BFM
MDGL icon

Boothbay Fund Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Boothbay Fund Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$997K Buy
+1,857
New +$951K 0.01% 1092
2025
Q4 		– Sell
-1,117
Closed -$512K – 2201
2025
Q3 		$512K Buy
+1,117
New +$417K 0.01% 1154
2022
Q1 		– Sell
-2,885
Closed -$244K – 2430
2021
Q4 		$244K Buy
+2,885
New +$237K 0.01% 1371
2021
Q3 		– Sell
-2,542
Closed -$248K – 2075
2021
Q2 		$248K Buy
2,542
+78
+3% +$9.23K 0.01% 1394
2021
Q1 		$288K Buy
2,464
+119
+5% +$13.9K 0.01% 1207
2020
Q4 		$261K Hold
2,345
– – 0.01% 1000
2020
Q3 		$278K Sell
2,345
-16,890
-88% -$1.83M 0.02% 829
2020
Q2 		$2.18M Sell
19,235
-4,188
-18% -$412K 0.15% 177
2020
Q1 		$1.56M Buy
23,423
+8,000
+52% +$667K 0.13% 192
2019
Q4 		$1.41M Buy
15,423
+5,266
+52% +$511K 0.12% 229
2019
Q3 		$876K Sell
10,157
-882
-8% -$82.8K 0.08% 340
2019
Q2 		$1.16M Buy
11,039
+1,239
+13% +$133K 0.11% 236
2019
Q1 		$1.23M Buy
+9,800
New +$1.22M 0.12% 193

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boothbay Fund Management's MDGL Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 1,857 shares worth $997K. The stake represents 0.01% of the portfolio and ranks #1092 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in MDGL as recently as Q3 2025.

Boothbay Fund Management first reported a position in MDGL in Q1 2019 and has held it in 13 quarters since. The position peaked at $2.18M in Q2 2020. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Boothbay Fund Management held 1,857 shares of Madrigal Pharmaceuticals worth $997K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Boothbay Fund Management position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1092 holding.
  • Boothbay Fund Management first reported a position in Madrigal Pharmaceuticals in Q1 2019 and has held it in 13 quarters since.
  • Boothbay Fund Management's Madrigal Pharmaceuticals position peaked at $2.18M in Q2 2020.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.